
Pharmacy Law Lowdown: Independent Pharmacy’s Most Challenging Legal Concerns
This episode explores ongoing developments in pharmacy law, specifically for independent pharmacies and their representatives who attended the 2025 NCPA Convention & Expo.
In episode 3 of the Pharmacy Law Lowdown, hosts Dae Lee, PharmD, Esq, CPBS, and Lucas Morgan, Esq, shareholders at Buchanan Ingersoll & Rooney, discuss the common concerns their independent pharmacy clients have been raising toward the end of 2025, from PBM reform and boards of pharmacy developments to rules and regulations behind the compounding of glucagon-like peptide-1 agonists.
Lee and Morgan recently gathered at the
“I think there's got to be an industry-wide education that needs to be taught in terms of why the drug spend goes up every year, why the manufacturers are paying a lot of rebates every year, and the patient premium and out-of-pocket cost goes up every year,” said Lee. “It's all because we have a vertically integrated system dominated by 3 PBMs: CVS Caremark, OptumRx, and Express Scripts.”
While hosts Lee and Morgan touched on a variety of pharmacy law topics—some significantly familiar to pharmacy experts, others completely novel—they gathered to provide their insights to independent pharmacy owners, operators, and employees all across the country. Learn from pharmacy law experts and common Drug Topics contributors to better understand what the legal pharmacy landscape is doing at this very moment.
Pharmacy Law Lowdown is a podcast offering from Drug Topics, hosted by
Be sure to tune in every month on Drug Topics for important updates in pharmacy and how to handle them. All episodes of Pharmacy Law Lowdown will be available in video format via
Don’t get left behind: Sign up today for our
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.














































































































































